as 07-26-2024 4:00pm EST
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Founded: | 2003 | Country: | United States |
Employees: | N/A | City: | RADNOR |
Market Cap: | 77.7M | IPO Year: | 2014 |
Target Price: | $10.86 | AVG Volume (30 days): | 1.0M |
Analyst Decision: | Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.64 | EPS Growth: | N/A |
52 Week Low/High: | $1.10 - $11.26 | Next Earning Date: | 08-08-2024 |
Revenue: | $28,288,000 | Revenue Growth: | 30.53% |
Revenue Growth (this year): | 29.5% | Revenue Growth (next year): | 47.84% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
MANNING MARTHA E | MRNS | SVP, GEN. COUNSEL & CORP. SEC. | Feb 20 '24 | Sell | $9.57 | 1,894 | $18,125.58 | 52,966 | SEC Form 4 |
Shafer Christina | MRNS | CHIEF COMMERCIAL OFFICER | Feb 20 '24 | Sell | $9.56 | 2,153 | $20,582.68 | 60,308 | SEC Form 4 |
Pfanstiel Steven | MRNS | CFO AND COO | Feb 16 '24 | Sell | $9.97 | 3,092 | $30,827.24 | 71,697 | SEC Form 4 |
Hulihan Joseph | MRNS | CHIEF MEDICAL OFFICER | Feb 16 '24 | Sell | $9.98 | 2,814 | $28,083.72 | 66,635 | SEC Form 4 |
Braunstein Scott | MRNS | CHAIRMAN AND CEO | Feb 16 '24 | Sell | $9.94 | 11,850 | $117,789.00 | 223,512 | SEC Form 4 |
MRNS Breaking Stock News: Dive into MRNS Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
MT Newswires
8 days ago
Business Wire
9 days ago
Zacks
a month ago
Clinical Trials Arena
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
Business Wire
a month ago
The information presented on this page, "MRNS Marinus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.